MedTrace Logo

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07029581 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-04-22

No results posted yet for this study

Summary

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

Conditions

  • Lewy Body Dementia Psychosis

Interventions

DRUG

ACP-204

Provided as 1 capsule, to be taken orally once daily

DRUG

Placebo

Provided as 1 capsule, to be taken orally once daily

Sponsors & Collaborators

  • ACADIA Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-06
Primary Completion
2028-02-29
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Czechia
  • France
  • Italy
  • Serbia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07029581 on ClinicalTrials.gov